Bota Bio, IMIDomics, MiRus
Munich-based mk2 Biotechnologies today announced the receipt of several million Euros in seed funding to accelerate the further growth of the company
The financing round was led by OCCIDENT, with significant funds also coming from primeCROWD and SeedBlink alongside co-financing from high net worth individuals.
mk2 Biotechnologies’ objective is to apply its unique platform approach for the synthesis and purification of authentic peptides at large scales which can be broadly applied in several market segments.
mk2 Biotechnologies GmbH develops, produces and investigates peptides at highest purity and quality standards using a revolutionary scalable synthesis technology. This way mk2 Biotechnologies enables the production of authentic peptides, regardless of their physical or chemical properties, at large scales and low cost. The pre-seed activities were financed with grants by the Zeidler-Forschungs-Stiftung and the funding programs “FLÜGGE” and “EXIST-Forschungstransfer”. Several early-stage start-up awards including the Science4Life Venture Cup and the TUM IdeAward had recognized the unique approach and its high potential.
https://www.mk2.bio/news/seed-funding
Macomics Raises £4.24M in Funding
Macomics, an Edinburgh, Scotland & Cambridge, UK-based immuno-oncology company, raised £4.24M in funding.
The round, which brought total funding raised to date to £7.44m, was led by Epidarex Capital with participation from new investor Caribou Property Limited and Scottish Enterprise.
The company intends to use the funds to expand: its macrophage-based therapeutics R&D portfolio, its facilities in Edinburgh and Cambridge, and its scientific team to support its accelerated R&D.
Co-founded in 2019 by Prof Jeffrey Pollard and Dr Luca Cassetta, now VP Immunology, and led by Dr Steve Myatt, Chief Executive Officer, and Dr Carola Ries, Chief Scientific Officer, Macomics provides immuno-oncology expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic. Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
Macomics Raises £4.24M in Funding | FinSMEs
Macomics, an Edinburgh, Scotland & Cambridge, UK-based immuno-oncology company, raised £4.24M in funding
Vira Health Raises £1.5M in Seed Funding
Vira Health, a London UK-based digital health company, raised £1.5M seed funding.
Backers included LocalGlobe, MMC Ventures, and angel investors including Megumi Ikeda, Managing Director, Hearst Ventures, Andrea Zitna of Elvie, former Spotify executive Sofia Bendz, founder of GoCardless Matt Robinson, and Simon Lambert, former CTO, MOO.com, and Treatwell.
The company intends to use the funds to invest further in product development and to expand the team.
Founded in 2020 by Andrea Berchowitz and Rebecca Love, Vira Health aims to make personalized menopause care accessible to all women by reducing the prevalence of later life conditions such as osteoporosis, cardiovascular disease, diabetes and dementia. Stella, the first product from the company, is a personalised app for menopause relief.
Vira Health Raises £1.5M in Seed Funding | FinSMEs
Vira Health, a London UK-based digital health company, raised £1.5M seed funding
Exo Raises $220M in Series C Funding
Exo, a Redwood City CA-based health information and devices company, raised $220M in Series C funding. The round was led by RA Capital Management with participation from BlackRock, Sands Capital, Avidity Partners and Pura Vida Investments. The company intends to use the funds to accelerate growth, expand operations and its business reach.
Led by CEO Sandeep Akkaraju, Exo leverages ultrasound silicon technology to advance a handheld ultrasound device that will, once regulatory approvals have been obtained, use new materials, processes and AI to generate high quality medical imaging for the entire body at an affordable cost. The company’s medical imaging ecosystem includes its proprietary point-of-care ultrasound workflow solution, Exo Works. The software works with nearly all point-of-care ultrasound devices and securely connects to the most common EMR and PACS systems used in hospitals to house imaging and communications.
Exo Raises $220M in Series C Funding | FinSMEs
Exo, a Redwood City CA-based health information and devices company, raised $220M in Series C funding
Rakuten Medical Closes $166M in Series D Funding
Rakuten Medical, a San Mateo CA-based biotechnology company focused on developing and commercializing innovative oncology products for multiple indications, raised $166M in Series D funding.
The preferred stock financing included $75m in new capital and the conversion of $91m of convertible promissory notes, including accrued interest. The round was led by General Catalyst with additional participation from existing investors, including Rakuten Group and SBI Group.
The company intends to use the funds to advance ongoing trials of ASP-1929 in several oncologic indications and research and development of additional pipeline therapies being developed using the Illuminox™ platform.
Led by Mickey Mikitani, Rakuten Medical is a clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its Illuminox™ platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis.
Rakuten Medical Closes $166M in Series D Funding
Rakuten Medical, a San Mateo CA-based biotechnology company focused on developing and commercializing innovative oncology products for multiple indications, raised $166M in Series D funding
Genomatica Raises US$ 118M in Series C Funding
Genomatica, a San Diego, CA-based company leveraging biology to remake everyday products and materials with a reduced environmental impact, raised 118m in Series C funding.
The round was led by Novo Holdings.
The company intends to use the funding to scale production for its portfolio of products and continue investing in new technologies to amplify the impact of sustainable materials across a range of industries.
Led by Christophe Schilling, Chief Executive Officer, Genomatica replaces widely-used chemicals and materials, traditionally derived from petroleum fossil fuels, with plant-based alternatives. The company has already commercialized sustainable materials used in plastics, spandex and cosmetics, and is working on plant-based nylon, household cleaners and more.
Genomatica Raises US$ 118M in Series C Funding
Genomatica, a San Diego, CA-based company leveraging biology to remake everyday products and materials with a reduced environmental impact, raised 118m in Series C funding
Ring Therapeutics Raises $117M in Series B Funding
Ring Therapeutics, a Cambridge, Mass.-based life sciences company, raised $117m in Series B funding.
Backers included Invus, Altitude Life Science Ventures, Partners Investment, UPMC Enterprises, funds and accounts advised by T. Rowe Price Associates, Inc., among others, alongside Flagship Pioneering.
The company intends to use the funds for the continued development and expansion of its novel vector Anellogy™ platform.
Founded by Flagship Labs in 2017 and led by Dr. Tuyen Ong, CEO, and Avak Kahvejian, Ph.D., Chairman, Ring has built a fully integrated and proprietary vector bioplatform to discover and vectorize anelloviruses to produce programmable medicines.
Ring Therapeutics Raises $117M in Series B Funding
Ring Therapeutics, a Cambridge, Mass.-based life sciences company, raised $117m in Series B funding
Strata Oncology Closes $90M Series C Financing
Strata Oncology, Inc., an Ann Arbor, Mich.-based precision oncology company advancing molecular indications for cancer therapies, raised $90m in Series C financing.
Wellington Management led the financing and was joined by other new investors including Cormorant Asset Management, Monashee Investment Management and Highside Capital Management.
Strata Oncology’s existing investors, including Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund also participated in the financing, which brings the company’s total raised to date to over $130m since inception. The proceeds will be used to accelerate the development of Strata Oncology’s personalized minimal residual disease (MRD) assay for early-stage cancers and advance its pipeline of novel RNA-based treatment selection tests for solid tumors.
Led by Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology is a precision oncology company involved in expanding its comprehensive genomic and transcriptomic profiling platform to deliver a portfolio of treatment selection tests for solid tumors. The platform, which integrates comprehensive genomic profiling and highly quantitative RNA expression profiling, enables comprehensive molecular insights from a single, minute tumor tissue specimen.
Strata Oncology Closes $90M Series C Financing | FinSMEs
Strata Oncology, Inc., an Ann Arbor, Mich.-based precision oncology company advancing molecular indications for cancer therapies, raised $90m in Series C financing
MiRus Raises $65M in Funding
MiRus, a Marietta, GA-based commercial stage life sciences company, completed a $65m funding round.
The round was led by Mammoth Scientific and multi-generational family offices who have supported MiRus from its inception.
The company intends to use the funds for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe®).
Led by Jay S. Yadav MD, Founder and CEO, MiRus is a life sciences company that has developed and is commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of spine, orthopaedic and structural heart disease. The company has broad global patent coverage for all medical implants made from Rhenium-based superalloys. The spine implants are distributed through hospitals and surgery centers around the country.
MiRus Raises $65M in Funding | FinSMEs
MiRus, a Marietta, GA-based commercial stage life sciences company, completed a $65m funding round
IgGenix Raises $25M in Series A1 Funding
IgGenix, Inc., a South San Francisco, CA-based biotechnology company focused on addressing allergic disease, raised $25m in Series A1 financing.
Khosla Ventures, which participated in IgGenix’s Series A funding in 2020, co-led the round along with Matthias Westman. New investors include Alexandria Venture Investments, ShangBay Capital and AllerFund.
The company intends to use the funds to further expand its discovery platform in food and nonfood allergies while accelerating its lead program into preclinical development.
Led by Chief Executive Officer Jessica Grossman, M.D., IgGenix is a biotechnology company that directly addresses food and other severe allergies by reengineering key antibodies involved in the allergic cascade.
IgGenix Raises $25M in Series A1 Funding | FinSMEs
IgGenix, Inc., a South San Francisco, CA-based biotechnology company focused on addressing allergic disease, raised $25m in Series A1 financing
IMIDomics Completes $16.5M Series A Financing
IMIDomics Inc., a San Francisco, CA-based drug discovery company focused on patients with immune-mediated inflammatory diseases (IMIDs), completed a $16.5m Series A financing round.
The round was led by DNS Capital with additional investment from Bristol Myers Squibb, The Pritzker Organization, Tao Capital and others.
The company intends to use the funds to accelerate its precision discovery efforts and accelerate technologies that are critical to the further development of new IMID treatments, while expanding teams in the US and Europe.
Founded in 2015, following a decade of incubation within Vall d’Hebron Hospital in Barcelona, during which the IMID-Biobank was built, and relocated to the United States in 2021, IMIDomics is a biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs).
IMIDomics Completes $16.5M Series A Financing | FinSMEs
IMIDomics Inc., a San Francisco, CA-based drug discovery company focused on patients with immune-mediated inflammatory diseases (IMIDs), completed a $16.5m Series A financing round
Bota Bio Raises $100M in Series B Funding
Bota Bio, a San Francisco CA-based and Hangzhou, China-based biotechnology company, raised $100M in Series B funding.
The round, which brought total funding to $145M, was led by Sequoia Capital China with participation from Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners and 5Y Capital.
The company intends to use the funds to expand global operations and build out its lab-to-pilot scale platform to facilitate the rapid scale-up and deployment of its product pipeline in consumer goods, food, nutrition, and pharmaceutical products.
Led by Cheryl Cui, Ph.D., co-founder and CEO, Bota Bio is a global industrial biotechnology company focused on programming biological systems and scaling sustainable production of biomolecules. The company has developed and deployed a technology platform – known as the Bota Freeway – that integrates advanced digital tools with lab automation. Bota Bio has also expanded synthetic biology’s design-build-test-learn cycle to include downstream process development and select non-traditional microbial strains, accelerating the design and evolution of enzymes and cell-based factories.
Bota Bio Raises $100M in Series B Funding | FinSMEs
Bota Bio, a San Francisco CA-based and Hangzhou, China-based biotechnology company, raised $100M in Series B funding
Joshua Kushner’s Thrive Capital leads $20M investment in Brazilian healthcare startup Pipo Saude – TechCrunch
Pipo Saude, a startup that developed a platform that sells and manages health care services for Brazilian companies, has raised $ 20 million in a Series A funding round.
Joshua Kushner’s Thrive Capital led the way, marking the first time the New York-based venture firm led an investment in a Brazilian startup. (Though Thrive has also invested money in Nubank and Loft in particular.)
Atlantico joined all existing donors, including Monashees, Kaszek and OneVC, as a new investor in the financing. Nubank co-founder and CEO David Velez and Cedar co-founder and CEO Florian Otto (and former CEO of Groupon in Brazil) also attended the round. Pipo Saude had raised $ 4.6 million from Nubank in June 2020 in a seed round led by Monashees and Kaszek, with the participation of OneVC and Velez from Nubank.
Manoela Mitchell (CEO), Thiago Torres (COO) and Vinicius Correa (CTO) founded Pipo Saude in July 2019 with the aim of delivering “an unparalleled experience” in buying and managing corporate health services combined with providing a care navigation platform for companies to offer employees. Put simply, its mission is to “transform” the health experience for companies and their employees.
